DOSSIER · 13F-HR · Q1 2026

Fairmount Funds Management LLC

Fairmount Funds's asset manager based in Omaha, NE — $1.4B in tracked AUM across 12 positions as of Q1 2026.

FF

Fairmount Funds·Omaha, NE·Asset Manager

CIK 0001802528 · last filed Mar 31, 2026

Total AUM

$1.4B

▲ 7.7%

vs prior

Holdings

12

—

positions

Whale Score

79

79

strong

Activity

—

no data

changes this Q

Top sector

Tech

4% weight

concentration

AI Analysis · Q1 2026 · Q1 2026

Portfolio Overview

Fairmount Funds Management LLC presents a highly specialized, concentrated investment portfolio with a total market value of $743.35 million as of the reporting period ended September 30, 2025. The portfolio is characterized by low diversification, comprising only 12 holdings, which indicates a high-conviction strategy. The fund experienced a decrease in assets under management (AUM) of approximately 3.7%, declining from $771.90 million in the previous quarter.

The portfo...

Quarter at a glance — Q1 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q1 2026.

#HoldingValueSharesWeight

01

DAMORA THERAPEUTICS INC

$226M8.7M16.3%

02

DIANTHUS THERAPEUTICS INC

$213M2.5M15.4%

03

COGENT BIOSCIENCES INC

$212M5.5M15.3%

04

SPYRE THERAPEUTICS INC

$203M4.0M14.6%

05

ORUKA THERAPEUTICS INC

$182M3.7M13.1%

06

VIRIDIAN THERAPEUTICS INC

$77M3.9M5.5%

07

ENLIVEN THERAPEUTICS INC

$73M1.9M5.3%

08

JADE BIOSCIENCES INC

$64M4.6M4.6%

09

CRESCENT BIOPHARMA INC.

$50M2.7M3.6%

10

ZENAS BIOPHARMA INC

$46M2.4M3.3%

Filing history

Filing history loading…